Giovanni Boschetti

Prof. Giovanni Boschetti

University of Padua, Padua, Italy
orcid

Research Focus & Metrics

Academic Career Length

61Years (1966-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in Cell
Verified
Journal Article
Closed access
JMJerome C. Martin
Jerome C. Martin
CCChristie Chang
Christie Chang
Giovanni BoschettiGiovanni Boschetti
Giovanni Boschetti
RURyan Ungaro
Ryan Ungaro
MGMamta Giri
Mamta Giri
EKEphraim Kenigsberg
Ephraim Kenigsberg

14 March 2014 in BMC Cancer
Verified
Journal Article
Open access
PDF file
OGOlivier Glehen
Olivier Glehen
GPGuillaume Passot
Guillaume Passot
LVLAURENT VILLENEUVE
LAURENT VILLENEUVE
DVDelphine Vaudoyer
Delphine Vaudoyer
SBSylvie Bin-Dorel
Sylvie Bin-Dorel
AGAlfredo Garofalo
Alfredo Garofalo
In Europe, gastric cancer remains diagnosed at advanced stage (serosal and/or lymph node involvement). Despite curative management combining perioperative systemic chemotherapy and gastrectomy with D1-D2 lymph node dissection, 5-year survival rates of T3 and/or N + patients remain under 30%. More than 50% of recurrences are peritoneal and/or locoregional. The use of adjuvant hyperthermic intraperitoneal chemotherapy that eliminates free cancer cells that can be released into peritoneal cavity during the gastrectomy and prevents peritoneal carcinomatosis recurrences, was extensively evaluated by several randomized trials conducted in Asia. Two meta-analysis reported that adjuvant hyperthermic intraperitoneal chemotherapy significantly reduces the peritoneal recurrences and significantly improves the overall survival. As it was previously done for the evaluation of the extension of lymph node dissection, it seems very important to validate on European or caucasian patients the results observed in trials performed in Asia.

1 November 2016 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
AAAMIOT Aurelien
AMIOT Aurelien
JGJean-Charles Grimaud
Jean-Charles Grimaud
Laurent Peyrin-birouletLaurent Peyrin-biroulet
Laurent Peyrin-biroulet
JFJerome Filippi
Jerome Filippi
BPBenjamin Pariente
Benjamin Pariente
JQJawad Al Qaddi
Jawad Al Qaddi

1 February 2017 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
MFMathurin Fumery
Mathurin Fumery
PSPhilippe Seksik
Philippe Seksik
CAClaire Auzolle
Claire Auzolle
NMNicolas Munoz-Bongrand
Nicolas Munoz-Bongrand
JGJean-Marc Gornet
Jean-Marc Gornet
MAMatthieu Allez
Matthieu Allez
We sought to determine the frequency of and risk factors for early (30-day) postoperative complications after ileocecal resection in a well-characterized, prospective cohort of Crohn’s disease patients. The REMIND group performed a nationwide study in 9 French university medical centers. Clinical-, biological-, surgical-, and treatment-related data on the 3 months before surgery were collected prospectively. Patients operated on between 1 September 2010 and 30 August 2014 were included. A total of 209 patients were included. The indication for ileocecal resection was stricturing disease in 109 (52%) cases, penetrating complications in 88 (42%), and medication-refractory inflammatory disease in 12 (6%). A two-stage procedure was performed in 33 (16%) patients. There were no postoperative deaths. Forty-three (21%) patients (23% of the patients with a one-stage procedure vs. 9% of those with a two-stage procedure, P=0.28) experienced a total of 54 early postoperative complications after a median time interval of 5 days (interquartile range, 4–12): intra-abdominal septic complications (n=38), extra-intestinal infections (n=10), and hemorrhage (n=6). Eighteen complications (33%) were severe (Dindo–Clavien III–IV). Reoperation was necessary in 14 (7%) patients, and secondary stomy was performed in 8 (4.5%). In a multivariate analysis, corticosteroid treatment in the 4 weeks before surgery was significantly associated with an elevated postoperative complication rate (odds ratio (95% confidence interval)=2.69 (1.15–6.29); P=0.022). Neither preoperative exposure to anti-tumor necrosis factor (TNF) agents (n=93, 44%) nor trough serum anti-TNF levels were significant risk factors for postoperative complications. In this large, nationwide, prospective cohort, postoperative complications were observed after 21% of the ileocecal resections. Corticosteroid treatment in the 4 weeks before surgery was significantly associated with an elevated postoperative complication rate. In contrast, preoperative anti-TNF therapy (regardless of the serum level or the time interval between last administration and surgery) was not associated with an elevated risk of postoperative complications.

11 January 2016 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
TGthe BIG RENAPE Group
the BIG RENAPE Group
CCC. S. Chia
C. S. Chia
BYB. You
B. You
EDE. Decullier
E. Decullier
DVD. Vaudoyer
D. Vaudoyer
OGOlivier Glehen
Olivier Glehen

1 December 2010 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
AOAbderrahim Oussalah
Abderrahim Oussalah
LELudovic Evesque
Ludovic Evesque
DLDavid Laharie
David Laharie
Xavier RoblinXavier Roblin
Xavier Roblin
Giovanni BoschettiGiovanni Boschetti
Giovanni Boschetti
Laurent Peyrin-birouletLaurent Peyrin-biroulet
Laurent Peyrin-biroulet
The American Journal of Gastroenterology is published by Nature Publishing Group (NPG) on behalf of the American College of Gastroenterology (ACG). Ranked the #1 clinical journal covering gastroenterology and hepatology*, The American Journal of Gastroenterology (AJG) provides practical and professional support for clinicians dealing with the gastroenterological disorders seen most often in patients. Published with practicing clinicians in mind, the journal aims to be easily accessible, organizing its content by topic, both online and in print. www.amjgastro.com, *2007 Journal Citation Report (Thomson Reuters, 2008)